Received: 1 June 2021
Accepted: 16 September 2021
First Online: 9 October 2021
: This study was approved by the ethics committee at the University of British Columbia. All participants read and signed a consent form agreeing to participate in this study.
: Not applicable.
: AB has received honorariums for presentations from Astrazeneca and Bosch. AK received funding from CSL Behring, Takeda and BioCryst for research and advisory board. Funders played no role in any aspect of this study. The rest of the authors declare that they have no relevant competing interests.